MBCC - Miami Breast Cancer Conference

Clinicians should consider the impact on subsequent therapies, overall survival, and median time to definitive deterioration with CDK 4/6 inhibitors.

Debu Tripathy, MD, University of Texas, MD Anderson Cancer Center at Houston, discussed the basic requirements of personalizing therapy.

The investigators performed a retrospective review of 215 patients age 65 years and older with TNBC or HER2+ breast cancer who underwent mastectomy from 2005 to 2020 at a single institution.